The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InINNOVATE Corp (VATE) announced that its subsidiary, MediBeacon, has received significant academic recognition for its kidney function monitoring technology. The Journal of the American Society of Nephrology (JASN) selected an article on MediBeacon’s transdermal glomerular filtration rate (tGFR) technology as a 2025 Editors’ Choice. This recognition highlights the clinical importance of the TGFR System, which is currently being deployed across several clinical centers of excellence. The technology aims to provide a more accurate and efficient method for measuring kidney function compared to traditional methods. By securing this endorsement, MediBeacon seeks to establish its proprietary system as a new global standard of care in nephrology. This development validates the commercial potential of INNOVATE Corp’s life sciences portfolio, potentially driving long-term value for shareholders.